HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MRVI
Maravai LifeSciences Holdings, Inc.
MRVI lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MRVI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRVI's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MRVI PE Valuation
MRVI has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MRVI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
MRVI has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MRVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | +$0.44 |
| Q2 2026 | -$0.52 | +$0.87 |
| Q1 2026 | -$0.71 | +$0.46 |
| Q4 2025 | -$0.90 | +$0.15 |
| Q3 2025 | -$0.87 | +$0.77 |
| Q2 2025 | -$1.39 | -$0.40 |
| Q1 2025 | -$1.17 | -$0.18 |
| Q4 2024 | -$1.05 | -$0.15 |
MRVI has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MRVI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MRVI on profitability, with a higher operating margin.
MRVI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.9M | +10% |
| Q2 2026 | $51.4M | +8.5% |
| Q1 2026 | $65.8M | +41% |
| Q4 2025 | $49.9M | -12% |
| Q3 2025 | $41.6M | -36% |
| Q2 2025 | $47.4M | -35% |
| Q1 2025 | $46.9M | -27% |
| Q4 2024 | $56.6M | -24% |
MRVI's revenue is recovering but still below its 2022 peak: $46M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | +54 points |
| Q2 2026 | -29% | +111 points |
| Q1 2026 | -3.3% | +102 points |
| Q4 2025 | -118% | -51 points |
| Q3 2025 | -99% | +161 points |
| Q2 2025 | -140% | -127 points |
| Q1 2025 | -105% | -76 points |
| Q4 2024 | -67% | -57 points |
MRVI's operating margin was −45% last quarter, up 54 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MRVI on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.5M | +$22.6M |
| Q2 2026 | $3.6M | +$16.8M |
| Q1 2026 | $4.2M | +$18.9M |
| Q4 2025 | -$24.9M | -$4.4M |
| Q3 2025 | -$18.1M | -498% |
| Q2 2025 | -$13.1M | -267% |
| Q1 2025 | -$14.6M | -$493K |
| Q4 2024 | -$20.5M | -$11.5M |
MRVI's free cash flow was −$13M over the past year, against −$66M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MRVI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MRVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.1M shares |
| 1 year | +3% | +4.4M shares |
| 3 years | +13% | +17.1M shares |
| 5 years | +33% | +36.8M shares |
| Available history | +54% | +52.4M shares |
MRVI has 149M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MRVI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -5.9x | Net Cash |
| Q3 2023 | -0.5x | Net Cash |
| Q2 2023 | -0.2x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.1x | Net Cash |
| Q2 2022 | -0.0x | Net Cash |
| Q1 2022 | 0.2x | Very low |
MRVI has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MRVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 55.9 | Neutral |
MRVI's weekly RSI is 59 (neutral) and its Stochastic is 56 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MRVI PE vs Healthcare Sector
| Metric | MRVI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRVI has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MRVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.51 | 2.3% above |
| 20 week MA | $7.09 | 8.3% above |
| 50 week MA | $5.11 | 50% above |
| 100 week MA | $4.09 | 88% above |
| 200 week MA | $6.78 | 13% above |
MRVI has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MRVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.9 | $29.7 | -0.5% |
| 2021 | $29.7 | $42.0 | +41% |
| 2022 | $42.0 | $14.0 | -67% |
| 2023 | $14.0 | $6.55 | -53% |
| 2024 | $6.55 | $5.50 | -16% |
| 2025 | $5.50 | $3.27 | -41% |
| 2026 YTD | $3.27 | $7.68 | +135% |
MRVI has the edge over HIMS on returns for 2026, with the stronger performance.